T3 — Technion Technology Transfer (Haifa)

T3 — Technion Technology Transfer is the technology-transfer arm of the Technion Research & Development Foundation (TRDF), managing intellectual property from the Technion – Israel Institute of Technology since 2005 under attorney Benjamin Soffer, with an 11-member team.

What it does: T3 evaluates and patents Technion inventions, negotiates industry licences, and runs acceleration and investment programmes — including AMIT, a medical-device incubator seeded with a donation exceeding $100 million from philanthropist Alfred E. Mann — to help researchers build and fund spin-off companies.

Results: according to the National Academy of Inventors' Top 100 Worldwide Universities ranking (based on US Patent and Trademark Office data) and Israeli press coverage, the Technion has placed in the global top 100 for US utility patents for five consecutive years, ranking 68th in 2022, 65th in 2023 (48 patents) and 81st in 2025 (46 patents) — the only Israeli university on the list each year. T3-linked spin-offs include Mazor Robotics (spinal-surgery robots, later acquired by Medtronic), Biosense (cardiac mapping, acquired by Johnson & Johnson), Corindus (robotic-assisted angioplasty, acquired by Siemens Healthineers) and Pluristem Therapeutics, plus the Parkinson's drug rasagiline (marketed as Azilect), developed with Teva Pharmaceuticals from Technion research.

Caveat: the NAI ranking itself cautions that patent counts do not indicate a university's research quality or licensing success, so the ranking should be read alongside T3's named spin-off exits rather than as a stand-alone impact measure.

Why it's a good practice: it shows a long-running, professionally managed university technology-transfer office with an independently ranked patent record and multiple medtech spin-offs later acquired by major global device and pharma companies.

Read the full analysis: https://t3.technion.ac.il/

Read the full analysis: https://t3.technion.ac.il/